DEF 14A: Tenon Medical Seeks Stockholder Approval for Director Elections, Equity Plan Amendments, and Nasdaq Compliance

Tenon Medical is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of directors, approval of amendments to the equity incentive plan, and compliance with Nasdaq listing rules.

Summary

• Tenon Medical is holding its 2024 Annual Meeting of Stockholders on July 23, 2024, virtually.
• Stockholders will vote on the election of seven directors, including Steven Foster, Richard Ginn, and others.
• A key proposal involves approving the terms of Series B Preferred Stock and warrants, along with amendments to Series A Preferred Stock, to comply with Nasdaq Listing Rule 5635(d).
• Stockholders will also vote on amendments to the Tenon Medical, Inc. 2022 Equity Incentive Plan to increase the share reserve by 1,100,000 shares and permit equity awards to individuals and legal entities.
• The appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be ratified.
• Additionally, stockholders will vote on approving the adjournment of the Annual Meeting, if necessary, to solicit additional proxies.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting routine proposals for stockholder approval. The tone is professional and optimistic, suggesting a positive outlook for the company's governance and future.

Positives

• The proposed amendments to the equity incentive plan aim to attract, retain, and engage highly motivated and qualified employees.
• Issuing equity awards to individuals and legal entities will allow the company to preserve working capital by issuing equity instead of paying cash for consulting services.
• The board believes that each proposal is in the best interests of the company and its stockholders.

Negatives

• The Series B Preferred Stock and Series B Warrants each have anti-dilution provisions which if triggered could cause the Company to be in violation of Nasdaq Listing Rule 5635(d).

Risks

• Failure to obtain stockholder approval for the Nasdaq Compliance Proposal could impact the company's ability to issue Series B Preferred Stock and warrants under the proposed terms.
• If stockholders do not ratify the appointment of Haskell & White LLP as the independent registered public accounting firm, the audit committee will reconsider its appointment.

Future Outlook

The company plans to issue up to 1,500,000 shares of Series B Preferred Stock on or before October 23, 2024, subject to market conditions and stockholder approval.

Management Comments

• The Board has determined that each proposal listed above is in the best interests of the Company and its stockholders and has approved each proposal.
• The Board recommends a vote FOR the Election of each director nominee (Proposal 1), FOR the Nasdaq Compliance Proposal (Proposal 2), FOR the approval of the 2022 Plan Amendment Proposal (Proposal 3), FOR the Auditor Appointment Proposal (Proposal 4) and FOR the Adjournment Proposal (Proposal 5).

Industry Context

The document does not explicitly compare Tenon Medical's proposals to specific industry trends or competitors. However, the need to comply with Nasdaq listing rules and the desire to attract and retain talent through equity compensation are common concerns in the medical device industry.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, the use of equity incentive plans is a common practice among publicly traded companies, particularly in the technology and medical device sectors, to align employee interests with those of shareholders.
• Companies like Medtronic, Stryker, and Johnson & Johnson also utilize equity compensation extensively.
• The specific terms of the Series B Preferred Stock and warrants would need to be compared to similar offerings by comparable companies to assess their competitiveness.

Related Party Transactions

• The Company entered into the Ferrari Consulting Agreement with Richard Ferrari, a founder of the Company and its Executive Chairman, pursuant to which Mr. Ferrari was to assume the role of Executive Chairman of the Company in exchange for compensation of $22,500 per month starting September 1, 2021.
• Under this consulting agreement Mr. Ferrari was paid a bonus of $350,000, as a result of the closing of our initial public offering in April 2022.
• In May of 2022 Mr. Ferrari was granted RSUs which had a grant date fair value of $2,427,020 and vest over three years, with one-third vesting in May of 2023 and the remaining two thirds vesting equally every six months over the following two years.
• The compensation paid to Mr. Ferrari during the fiscal year ended December 31, 2023, totaled $247,500.

Stakeholder Impact

• Approval of the proposals could impact shareholders through potential dilution from the issuance of new shares and warrants.
• Employees may benefit from the amended equity incentive plan.
• The company's ability to raise capital and comply with Nasdaq listing rules could affect its overall financial health and long-term prospects.

Next Steps

• Stockholders need to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting on July 23, 2024.
• The company will proceed with the issuance of Series B Preferred Stock and warrants, subject to stockholder approval and market conditions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Equity Incentive Plan, Nasdaq Compliance, Series B Preferred Stock, Warrants, Auditor Appointment, Tenon Medical